Avanos Medical (AVNS) Cash & Equivalents (2013 - 2026)

Avanos Medical has disclosed Cash & Equivalents across 14 years of filings, most recently posting $65.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $65.6 million, down 32.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.6 million (down 32.37% YoY), and the FY2025 annual result was $89.8 million, down 16.62% from the prior year.
• Cash & Equivalents came in at $65.6 million for Q1 2026 at Avanos Medical, down from $89.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $127.7 million in Q4 2022 to a low of $65.6 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $92.2 million (2024), against an average of $94.5 million.
• Across the five-year window, Cash & Equivalents advanced 27.97% in 2025 and sank 32.37% in 2026, its largest moves.
• Avanos Medical's Cash & Equivalents stood at $127.7 million in 2022, then plunged by 31.32% to $87.7 million in 2023, then grew by 22.81% to $107.7 million in 2024, then slipped by 16.62% to $89.8 million in 2025, then dropped by 26.95% to $65.6 million in 2026.
• The last three Cash & Equivalents figures came in at $65.6 million (Q1 2026), $89.8 million (Q4 2025), and $70.5 million (Q3 2025), per Business Quant data.